Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEP-1 for Treatment of COVID-19 Infection
NCT04627233Phase 1Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial in coronavirus disease 2019 (COVID-19) comparing Placebo with HEP-1 (2 arms). Primary endpoints: Time to clinical improvement of disease symptoms at 7 days, Duration of Hospitalization at 28 days and 1 more. Status: unknown.
02
Drugs
Human Ezrin Peptide 1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04627233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627233.